Choices and Experiences Around Closed-loop Therapy in Type 1 Diabetes

NCT ID: NCT07177404

Last Updated: 2025-09-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-30

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Type 1 diabetes requires a lot of work to try to keep glucose levels in the target range. Hybrid closed- loop, also known as artificial pancreas, takes glucose readings from a sensor (continuous glucose monitor) and uses an algorithm to tell an insulin pump how much insulin to deliver. Hybrid closed-loop has currently been rolled out to many people with type 1 diabetes in England. We are keen to develop a deeper understanding of the perspective of people living with type 1 diabetes who have choices about which hybrid closed-loop systems fit their needs.

The main purpose of this study is to explore the choices and experiences of people living with type 1 diabetes regarding closed-loop therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a cross-sectional online survey study, which involves people with type 1 diabetes who use closed-loop, wait to start closed-loop or considering closed-loop.

The primary objective of the study is to explore the factors driving the choices of people living with type 1 diabetes regarding closed-loop therapy.

The secondary objectives of the study are:

* To understand what treatment satisfaction with closed-loop therapy means to people living with type 1 diabetes
* To understand what additional support is needed for people with type 1 diabetes using closed-loop therapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabete Mellitus Type 1 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: ≥18 years (no upper age limit)
* Type 1 diabetes (any duration)
* People who use closed-loop therapy or wait to start closed-loop therapy or considering closed-loop therapy in the future
* Ability to give informed consent

Exclusion Criteria

* Any other type of diabetes apart from type 1 diabetes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Nottingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospitals of Derby and Burton

Derby, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emma Wilmot

Role: CONTACT

0044 1332 258268

Alexandros Liarakos

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexandros Liarakos

Role: primary

0044 1332 258268

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

25026

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.